Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors, developed from foundational research on Jak3 signaling, are now a key therapeutic class for inflammatory bowel disease (IBD), meaning more of your endoscopy patients may present on these medications for conditions like ulcerative colitis and Crohn's disease.
• Because Jak3 and related kinases mediate signaling for multiple cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) involved in immune regulation, patients on JAK inhibitors are at increased risk for infection and may require modified pre-procedure screening or precautions.
• Understanding that JAK inhibitors work by blocking intracellular cytokine signaling—rather than neutralizing cytokines directly, as biologics do—helps nurses better explain treatment rationale to patients and anticipate different monitoring needs (e.g., bloodwork for cytopenias, lipid panels) compared to anti-TNF or anti-integrin therapies.
• As this drug class expands into conditions such as alopecia areata, atopic dermatitis, and psoriatic arthritis in addition to IBD, GI nurses may increasingly encounter patients with overlapping autoimmune diagnoses and polypharmacy considerations affecting endoscopic care.

Clinical Relevance

This research summary highlights the scientific origins of JAK inhibitors, a drug class that has moved from bench discovery to bedside application in gastroenterology. The foundational identification of Jak3 and its role in common gamma chain cytokine signaling led directly to the development of small-molecule JAK inhibitors now used to treat moderate-to-severe ulcerative colitis, and increasingly studied in Crohn's disease. For endoscopy and GI nurses, this means patient intake and medication reconciliation should routinely capture JAK inhibitor use (tofacitinib, upadacitinib, and others), as these agents carry distinct safety considerations compared to older biologic therapies.

Because JAK inhibitors act broadly on cytokine signaling pathways involved in immune surveillance, patients may have heightened susceptibility to infections, including herpes zoster reactivation, and may require specific pre-procedure assessments. Nurses coordinating bowel preparation instructions, sedation plans, and post-procedure monitoring should be aware of boxed warnings associated with this drug class regarding thrombosis, malignancy, and major adverse cardiovascular events, particularly in older patients or those with cardiovascular risk factors. This knowledge supports more thorough pre-procedure risk stratification and patient education during consent conversations.

From a professional development standpoint, understanding the cytokine biology behind JAK inhibition—including its relevance to the "cytokine storm" phenomenon seen in COVID-19—equips nurses to engage more confidently in multidisciplinary discussions about IBD management, biologic/small-molecule sequencing, and treat-to-target strategies. As GI units increasingly manage complex immunosuppressed patients, nursing competency in recognizing drug-specific risks strengthens both patient safety protocols and interdisciplinary communication with hepatology, rheumatology, and infectious disease teams who may co-manage these patients.

Bottom Line

JAK inhibitors, born from basic science discoveries about Jak3 and cytokine signaling, are an expanding treatment option for IBD and other autoimmune conditions—GI nurses should prioritize identifying JAK inhibitor use during patient assessment and remain alert to this class's distinct infection, thrombosis, and cardiovascular risk profile when planning endoscopic procedures and patient education.